The analgesics market is on track to achieve a revenue of US$ 91.62 billion in 2024. The market share of analgesics is increasing continuously in the drugs and medication sector, which has the ability to translate into a CAGR of 4.6% during the forecast period. This promising growth of the industry is slated to culminate at a valuation of about US$ 143.65 billion by 2034.
| Report Attribute | Details |
|---|---|
| Market Size (2024) | US$ 91.62 billion |
| Market Anticipated Forecast Value (2034) | US$ 143.65 billion |
| Market Projected Growth Rate (2024 to 2034) | 4.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Rising cases of opioid dependency and the abuse of painkillers have led to the establishment of different abuse-deterrent systems and laws, which are put forward as a deterrent to the market. On the other hand, the forecast period is characterized by remunerative opportunities through technological development in the pharmaceutical industry to manufacture advanced versions of these drugs.
The market was valued at US$ 66.36 billion in 2018. The global market expanded at 5.6% CAGR over the past 5 years between 2018 and 2023. The overall market value was about US$ 87.14 billion by 2023.
| Attributes | Details |
|---|---|
| Market Value (2018) | US$ 66.36 billion |
| Market Revenue (2023) | US$ 87.14 billion |
| Market Historical Growth Rate (CAGR 2018 to 2023) | 5.6% CAGR |
Principal Consultant
Long-term diseases, and cardiovascular disorders, in particular, contribute to industry growth. A rise in the prevalence of diseases such as cancer has also increased the number of people suffering from chronic pain.
Improving healthcare infrastructure is a significant factor influencing the growth rate of the overall market. Further, various government organizations are striving to improve healthcare infrastructure by increasing funding, which will further affect market dynamics.
The introduction of novel drug delivery systems has created more opportunities for market suppliers in the last few years. Further development of novel drug delivery systems and its spread in African and Asian countries has the potential to create and improve the future outlook for opioid analgesics.
Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased sales globally. According to the International Association for the Study of Pain (IASP), around 20-30% of opioids prescribed for chronic pain are being misused. Besides this, as per the association, up to 10% of the total opioid consumers are addicted to them.
Biotechnology is limiting the growth of the market due to the growth of biologics for treating inflammatory and neuropathic pain. Biologics are considered more effective than analgesics, which only provide effective pain relief for 50% of patients, and are therefore seeing greater use.
The table below lists the countries with a sizable market share and high growth opportunities.
| Regional Market Comparison | CAGR (2024 to 2034) |
|---|---|
| United States | 3.2% |
| Germany | 3.4% |
| United Kingdom | 3.1% |
| Thailand | 5.4% |
| India | 6.8% |
Government initiatives to favor the utilization of pain relief drugs exhibit high demand, expected at 3.2% CAGR through the course of the forecast period. The pain relief medication industry is gaining prominence in the United States due to the growing percentage of people susceptible to chronic and lifestyle-related diseases.
As per the documentation in 2016 by the National Health Institute, over 20% of adults in the USA suffer from chronic pain and 8% have high-impact chronic pain. Additionally, the US Food and Drug Administration's (USFDA) approval of a strong pipeline of effective drugs is expected to support market growth.
The rising number of over-the-counter (OTC) pharmacies in the country is anticipated to result in the growth of the regional market at 3.4% CAGR through 2034. The trend of self-medication in Germany is highly prevalent. Sales of non-prescription analgesics via OTC pharmacies in Germany have been characterized as one of the main drivers of the market in the country.
There has been a swift trend favoring analgesic utilization in the United Kingdom that has the potential to translate into a CAGR of 3.1% through 2034. The country is registering higher demand mostly concentrated in the older or geriatric population aiming to achieve a better quality of life.
Commercializing opioid-tolerant drugs is found to be one of the main opportunities for the United Kingdom market players in the opioid drugs sector.
The market in India is projected to expand at a CAGR of 6.8% over the projected years. According to research on analgesic utilization in public hospitals in India, the utilization of NSAIDs and opioids showed a higher trend than other types of analgesics.
For pain management, the governing body of India is encouraging doctors to prescribe non-opioid analgesics, which provides an opportunity for companies to introduce novel non-opioid drugs.
Additionally, key manufacturers are present in the market to manufacture and distribute analgesic drugs, and consumer expenditure on healthcare is increasing, factors positively impacting the market in the country.
Thailand is experiencing a remarkable rise in painkiller consumption resulting in a forecasted CAGR of 5.4% for the market. The introduction of non-opioid analgesics in the country is expected to promote the sales of non-steroidal anti-inflammatory drugs over the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attributes | Details |
|---|---|
| Top Pain Indication Segment | Surgical Pain |
| Total Market Share in 2024 to 2034 | 45.6% |
Surgical pain is slotted in to hold a revenue share of 45.6% in 2024. The higher adoption of surgical procedures worldwide is the key reason driving the surgical pain segment. Also, the impact of the NSAIDs market on improving healthcare outcomes has leveraged the use of analgesic painkillers during surgery.
The growing prevalence of diseases requiring surgical treatment, like heart disease, cancer, stroke, and arthritis is poised to further increase the demand for painkillers in this segment.
| Attributes | Details |
|---|---|
| Top Drug Class Segment | Opioids |
| Total Market Share in 2024 | 47.8% |
Based on drug class, opioid is expected to be used for the production of 47.8% of the analgesics in 2024. High demand for opioid drug classes is because of the rising burden of chronic pain and inflammation incidences globally.
The controlled sales of opioid analgesics contribute to a higher market share for hospital pharmacies. Further, private and government funding for pharmaceutical manufacturing segments and Research and Development activities for developing opioid products have boosted the growth of this segment.
Key players are focusing on novel and innovative approaches for the development of non-opioid or non-addictive formulations for pain management. Leading companies are strengthening their product portfolio and global footprint through acquisitions.
The strategy of expansion, new product launches, and approvals by key manufacturers is further strengthening their market presence. Besides these, mergers and acquisitions have emerged as key growth strategies adopted by market players.
Various acquisition strategies and product launches have been employed by new market players to increase their market presence. For example, Advil Dual Action was launched by GlaxoSmithKline PLC on September 10, 2020, and consists of two or more pain-relieving ingredients such as ibuprofen and acetaminophen.
Recent Developments in the Global Analgesics Market
The market is estimated to be around US$ 91.62 billion in 2024.
The market is set to develop at 4.6% CAGR during the forecast period.
The market is predicted to be valued at US$ 143.65 billion by 2034.
Opioids are anticipated to account for nearly 47.8% revenue share of the global market in 2024.
India is predicted to witness a CAGR of 6.8% in sales of analgesics through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Drug Class, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Drug Class, 2024 to 2034 5.3.1. Opioids 5.3.2. NSAIDs 5.3.3. Local Anaesthetics 5.3.4. Acetaminophen 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Class, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034 6.3.1. Surgical Pain 6.3.2. Cancer Pain 6.3.3. Neuropathic Pain 6.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Route of Administration, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Route of Administration, 2024 to 2034 7.3.1. Oral 7.3.2. Parenteral 7.3.3. Transdermal 7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023 8.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 8.3.1. Hospital Pharmacies 8.3.2. Retail Pharmacies 8.3.3. Drug Store 8.3.4. Clinics 8.3.5. Others 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023 9.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034 9.3.1. North America 9.3.2. Latin America 9.3.3. Western Europe 9.3.4. Eastern Europe 9.3.5. South Asia and Pacific 9.3.6. East Asia 9.3.7. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. USA 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Indication 10.2.4. By Route of Administration 10.2.5. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Indication 10.3.4. By Route of Administration 10.3.5. By Distribution Channel 10.4. Key Takeaways 11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Indication 11.2.4. By Route of Administration 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Indication 11.3.4. By Route of Administration 11.3.5. By Distribution Channel 11.4. Key Takeaways 12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. UK 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Western Europe 12.2.2. By Drug Class 12.2.3. By Indication 12.2.4. By Route of Administration 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Indication 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Key Takeaways 13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. Poland 13.2.1.2. Russia 13.2.1.3. Czech Republic 13.2.1.4. Romania 13.2.1.5. Rest of Eastern Europe 13.2.2. By Drug Class 13.2.3. By Indication 13.2.4. By Route of Administration 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Key Takeaways 14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Bangladesh 14.2.1.3. Australia 14.2.1.4. New Zealand 14.2.1.5. Rest of South Asia and Pacific 14.2.2. By Drug Class 14.2.3. By Indication 14.2.4. By Route of Administration 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Indication 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Key Takeaways 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Drug Class 15.2.3. By Indication 15.2.4. By Route of Administration 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 16.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 16.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Indication 16.2.4. By Route of Administration 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Indication 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2023 17.1.2.1. By Drug Class 17.1.2.2. By Indication 17.1.2.3. By Route of Administration 17.1.2.4. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2023 17.2.2.1. By Drug Class 17.2.2.2. By Indication 17.2.2.3. By Route of Administration 17.2.2.4. By Distribution Channel 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2023 17.3.2.1. By Drug Class 17.3.2.2. By Indication 17.3.2.3. By Route of Administration 17.3.2.4. By Distribution Channel 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2023 17.4.2.1. By Drug Class 17.4.2.2. By Indication 17.4.2.3. By Route of Administration 17.4.2.4. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2023 17.5.2.1. By Drug Class 17.5.2.2. By Indication 17.5.2.3. By Route of Administration 17.5.2.4. By Distribution Channel 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2023 17.6.2.1. By Drug Class 17.6.2.2. By Indication 17.6.2.3. By Route of Administration 17.6.2.4. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2023 17.7.2.1. By Drug Class 17.7.2.2. By Indication 17.7.2.3. By Route of Administration 17.7.2.4. By Distribution Channel 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2023 17.8.2.1. By Drug Class 17.8.2.2. By Indication 17.8.2.3. By Route of Administration 17.8.2.4. By Distribution Channel 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2023 17.9.2.1. By Drug Class 17.9.2.2. By Indication 17.9.2.3. By Route of Administration 17.9.2.4. By Distribution Channel 17.10. Poland 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2023 17.10.2.1. By Drug Class 17.10.2.2. By Indication 17.10.2.3. By Route of Administration 17.10.2.4. By Distribution Channel 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2023 17.11.2.1. By Drug Class 17.11.2.2. By Indication 17.11.2.3. By Route of Administration 17.11.2.4. By Distribution Channel 17.12. Czech Republic 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2023 17.12.2.1. By Drug Class 17.12.2.2. By Indication 17.12.2.3. By Route of Administration 17.12.2.4. By Distribution Channel 17.13. Romania 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2023 17.13.2.1. By Drug Class 17.13.2.2. By Indication 17.13.2.3. By Route of Administration 17.13.2.4. By Distribution Channel 17.14. India 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2023 17.14.2.1. By Drug Class 17.14.2.2. By Indication 17.14.2.3. By Route of Administration 17.14.2.4. By Distribution Channel 17.15. Bangladesh 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2023 17.15.2.1. By Drug Class 17.15.2.2. By Indication 17.15.2.3. By Route of Administration 17.15.2.4. By Distribution Channel 17.16. Australia 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2023 17.16.2.1. By Drug Class 17.16.2.2. By Indication 17.16.2.3. By Route of Administration 17.16.2.4. By Distribution Channel 17.17. New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2023 17.17.2.1. By Drug Class 17.17.2.2. By Indication 17.17.2.3. By Route of Administration 17.17.2.4. By Distribution Channel 17.18. China 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2023 17.18.2.1. By Drug Class 17.18.2.2. By Indication 17.18.2.3. By Route of Administration 17.18.2.4. By Distribution Channel 17.19. Japan 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2023 17.19.2.1. By Drug Class 17.19.2.2. By Indication 17.19.2.3. By Route of Administration 17.19.2.4. By Distribution Channel 17.20. South Korea 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2023 17.20.2.1. By Drug Class 17.20.2.2. By Indication 17.20.2.3. By Route of Administration 17.20.2.4. By Distribution Channel 17.21. GCC Countries 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2023 17.21.2.1. By Drug Class 17.21.2.2. By Indication 17.21.2.3. By Route of Administration 17.21.2.4. By Distribution Channel 17.22. South Africa 17.22.1. Pricing Analysis 17.22.2. Market Share Analysis, 2023 17.22.2.1. By Drug Class 17.22.2.2. By Indication 17.22.2.3. By Route of Administration 17.22.2.4. By Distribution Channel 17.23. Israel 17.23.1. Pricing Analysis 17.23.2. Market Share Analysis, 2023 17.23.2.1. By Drug Class 17.23.2.2. By Indication 17.23.2.3. By Route of Administration 17.23.2.4. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Indication 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. Pfizer Inc. 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.1.5.2. Product Strategy 19.1.1.5.3. Channel Strategy 19.1.2. Sun Pharmaceutical Industries, Inc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.2.5.2. Product Strategy 19.1.2.5.3. Channel Strategy 19.1.3. Mallinckrodt Pharmaceuticals 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.3.5.2. Product Strategy 19.1.3.5.3. Channel Strategy 19.1.4. AbbVie Inc. (Allergan plc) 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.4.5.2. Product Strategy 19.1.4.5.3. Channel Strategy 19.1.5. Teva Pharmaceuticals 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.5.5.2. Product Strategy 19.1.5.5.3. Channel Strategy 19.1.6. Boehringer Ingelheim International GmbH 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.6.5.2. Product Strategy 19.1.6.5.3. Channel Strategy 19.1.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson] 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.7.5.2. Product Strategy 19.1.7.5.3. Channel Strategy 19.1.8. Endo Pharmaceuticals Inc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.8.5.2. Product Strategy 19.1.8.5.3. Channel Strategy 19.1.9. Purdue Pharmaceuticals L.P. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.9.5.2. Product Strategy 19.1.9.5.3. Channel Strategy 19.1.10. Assertio Therapeutics, Inc. 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 19.1.10.5.2. Product Strategy 19.1.10.5.3. Channel Strategy 19.1.11. Bayer AG 19.1.11.1. Overview 19.1.11.2. Product Portfolio 19.1.11.3. Profitability by Market Segments 19.1.11.4. Sales Footprint 19.1.11.5. Strategy Overview 19.1.11.5.1. Marketing Strategy 19.1.11.5.2. Product Strategy 19.1.11.5.3. Channel Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Analgesics Market
